ReviewCurrent oncology reports2020
Diagnostic and Therapeutic Considerations for Extramedullary Leukemia.
Review in Current oncology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 36 citations in OpenAlex.
- Leukemia cutis as the first manifestation of acute myeloid leukemia.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Article
- Nanotechnology in Hematology: Enhancing Therapeutic Efficacy With Nanoparticles.Health science reports · 2025Article
- Diagnostic approach to leukemia cutis : A differential diagnostic step-by-step algorithm.American journal of clinical pathology · 2025Review
- Diagnostic Approaches in Myeloid Sarcoma.Current issues in molecular biology · 2025Review
- Isolated cutaneous myeloid sarcoma preceding acute myeloid leukemia: a case report and literature review.Dermatology reports · 2025Article
- A Rare Cervical Manifestation of Acute Myeloid Leukemia: Granulocytic Sarcoma Simulating as a Gynecologic Tumor.Case reports in oncological medicine · 2025Article
- Case report: Orbital myeloid sarcoma: a report of two rare cases and review of the literature.Pathology oncology research : POR · 2024Review
- A case report of acute promyelocytic leukemia with myeloid sarcoma of the lumbar spine and literature review.Frontiers in medicine · 2024Review
- Review
- A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges.Frontiers in pharmacology · 2023Review
- Article
- Article
- Clinical characteristics, treatment, and prognosis of 118 cases of myeloid sarcoma.Scientific reports · 2022Article
- Extramedullary Acute Leukemia-Still an Unforeseen Presentation.Hematology reports · 2022Article
- Isolated Myeloid Sarcoma: A Diagnostic Dilemma.Cureus · 2022Article
- Clinical characteristics, pathology features and outcomes of pediatric myeloid sarcoma: A retrospective case series.Frontiers in pediatrics · 2022Article
- Clinical and molecular characterization of myeloid sarcoma without medullary leukemia.Leukemia & lymphoma · 2021Article
- Radiation Therapy for Chemotherapy Refractory Gingival Myeloid Sarcoma.Frontiers in oncology · 2021Article
- Successful Treatment of Myeloid Sarcoma in an Elderly Patient with Myelodysplastic Syndrome with Reduced-Dose Azacitidine.Case reports in hematology · 2021Article
- Dermatological manifestations of hematologic neoplasms. Part I: secondary specific skin lesions.Anais brasileiros de dermatologiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe purpose of this review is to summarize the current literature on the presentation, diagnosis, and treatment options available for extramedullary (EM) manifestations of leukemia including myeloid sarcoma (MS) and leukemia cutis (LC). RECENT
findingsAdvanced imaging using 18FDG-PET/CT is an effective screening tool for EM manifestations of leukemia. The role of radiation therapy has been more clearly delineated in the treatment of both MS and LC. FDA-approved targeted agents have improved outcomes in patients with AML but have not demonstrated improvements specifically for EM; however, a checkpoint inhibitor, Ipilimumab, holds promise in impacting local control for the treatment of AML-related EM. EM manifestations of leukemia pose significant therapeutic challenges. Treatment of EM is predicated on multiple factors including the presence of concomitant bone marrow involvement, AML-risk classification, and timing of presentation at initial diagnosis or relapse following systemic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.